一天服用阿司匹林可以消除MASLD吗?
Amedeo Lonardo1, Ming-Hua Zheng2,3,4,5
1Department of Internal Medicine, Ospedale Civile di Baggiovara (-2023), Azienda Ospedaliero-Universitaria di Modena, 41100, Modena, Italy. a.lonardo@libero.it.
阿司匹林在治疗与代谢功能障碍相关的脂肪性肝病 (MASLD) 中表现有前途. 研究表明,它可以减少肝脏脂肪和纤维化,可能预防肝癌.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 阿司匹林是一种广泛使用的药物,具有多种治疗应用.
- 最近的研究表明,阿司匹林在肝脏疾病中的潜在益处.
- 非酒精性脂肪性肝病/代谢功能障碍脂肪性肝病/代谢功能障碍相关的脂肪性肝病 (NAFLD/MAFLD/MASLD) 是一个日益严重的健康问题.
研究的目的:
- 审查目前关于阿司匹林在MASLD中的疗效的证据.
- 探索阿司匹林潜在的肝保护作用背后的机制.
- 讨论阿司匹林作为MASLD治疗剂的含义.
主要方法:
- 摘要和讨论最新的随机对照试验对阿司匹林的非肝性MASLD.
- 对阿司匹林对肝脏影响的现有流行病学数据的审查.
- 检查拟议的机制,包括对脂肪组织,肝脏和性别差异的影响.
主要成果:
- 有证据表明,阿司匹林可能在肝脏中具有抗和抗纤维性质.
- 在肝细胞癌的初级预防中的潜在作用.
- 观察到对脂肪组织和肝脏的影响,考虑到基于性别的差异.
结论:
- 阿司匹林显示出作为MASLD的"肝病药"的潜力.
- 新发现需要进一步的全面调查.
- 需要进行更多的研究,才能充分阐明阿司匹林在管理MASLD中的作用.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
02:44Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models
Published on: July 26, 2024
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Cholinergic Antagonists: Pharmacokinetics
